Millendo Therapeutics, Inc. MLND, a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews at the following healthcare investor conferences:
- 2019 SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on Tuesday, May 7, 2019 in New York, where one-on-one investor meetings will be held.
- 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 10:00 a.m. EST in New York. A live webcast of the presentation will be available on the Investors & Media section of Millendo's website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a
late-stage biopharmaceutical company focused on developing novel
treatments for orphan endocrine diseases where current therapies do not
exist or are insufficient. As a leading orphan endocrine company,
Millendo creates distinct and transformative treatments where there is a
significant unmet medical need. The company is currently advancing
livoletide for the treatment of Prader-Willi syndrome and nevanimibe for
the treatment of classic congenital adrenal hyperplasia and endogenous
Cushing's syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005167/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.